Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer.

Nicolo Matteo Luca BattistiMaria Sol AndresKarla A LeeSivatharshini RamalingamTamsin NashStephanie MappouridouNishanthi SenthivelKalaprapa AsavisanuMariam ObeidElli-Sophia TripodakiVasileios AngelisEmily FlemingEmily F GoodeSusan JohnStuart D RosenMark AllenSusannah StanwayAlexander R LyonAlistair Ring

Published in: Breast cancer research and treatment (2021)

Cardiotoxicity was relatively common (16.6%), but symptomatic heart failure on trastuzumab was rare in our cohort. The HFA-ICOS score identifies patients at high risk of cardiotoxicity.

Keyphrases

heart failure
early breast cancer
epidermal growth factor receptor
metastatic breast cancer
left ventricular
palliative care
acute heart failure
cardiac resynchronization therapy
risk factors
atrial fibrillation
genome wide
gene expression